The European Commission (EC) has approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies ...

Celularity Inc.’s CELU share price has dipped by 11.11%, which has investors questioning if this is right time to buy.

Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.